Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Warm Antibody Autoimmune Hemolytic Anemia: early-phase trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Warm Antibody Autoimmune Hemolytic Anemia: 2 US clinical trials tracked, none currently recruiting.
Warm Antibody Autoimmune Hemolytic Anemia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Rigel Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition warm-antibody-autoimmune-hemolytic-anemia
OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Warm Antibody Autoimmune Hemolytic Anemia has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Warm Antibody Autoimmune Hemolytic Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Warm Antibody Autoimmune Hemolytic Anemia is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
NCT04657094
A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)
Rigel Pharmaceuticals
NCT02612558
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Warm Antibody Autoimmune Hemolytic Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Warm Antibody Autoimmune Hemolytic Anemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Warm Antibody Autoimmune Hemolytic Anemia page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Warm Antibody Autoimmune Hemolytic Anemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Rigel Pharmaceuticals sponsors the most Warm Antibody Autoimmune Hemolytic Anemia trials on record, review their full trial history before evaluating a specific study. See Rigel Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Warm Antibody Autoimmune Hemolytic Anemia condition card totals 2 registered trials; most-linked intervention Fostamatinib 150 mg bid; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.